Berrien-Elliott, Melissa M <br/><br/>
Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells.  [electronic resource] 

 -  Cancer immunology research  Feb 2015 
 - 116-24 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2326-6074 
<br/><br/><label>Standard No.: </label>10.1158/2326-6066.CIR-14-0159  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>CD8-Positive T-Lymphocytes--immunology<br/>Cell Line, Tumor<br/>Cytotoxicity, Immunologic--immunology<br/>Gene Expression Regulation, Neoplastic--immunology<br/>Immune Tolerance--immunology<br/>Immunotherapy--methods<br/>Leukemia, Experimental--genetics<br/>Lymphocytes, Tumor-Infiltrating--immunology<br/>Mice, Transgenic<br/>Neoplasm Transplantation<br/>T-Box Domain Proteins--immunology<br/>T-bet Transcription Factor